What make differences in the outcome of adjuvant treatments for resected gastric cancer?

doi:10.3748/wjg.v20.i33.11567

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 33

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6324)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

527

WORD

255

HTML

3349

Tables (1-3)

260

Sum=4391

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1060

Download

873

Sum=1933

Sep 7, 2014 (publication date) through Mar 7, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Sep 7, 2014; 20(33): 11567-11573
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11567

Table 1 Recent epoch making adjuvant trials showing survival benefit

Reporter/group	Regimen	Patients	3 ysr/treated	3 ysr/control
Macdonald/2001 (SWOG INT0116)	FL + (Rad. + FL)	Curat. D2	50	41
Cunningham/2006 (MAGIC)	EPF (peri-op.)	Curat.	36¹	23¹
Sakuramoto/2007 (ACTS-GC)	S-1	II-III	80.1	70.1
Ychou/2011 (FNCLCC/FFCD)	CDDP + 5-FU (peri-op.)	Curat.res.	38¹	24¹
Bang/2012 (CLASSIC)	Cape. + Oxal.	II-IIIB	74	51

¹Five year survival rate. 3 ysr: 3 year survival rate (%); FL: 5fluorouracil + leucovorin, Rad.: Radiation; Curat.: Curative; EPF: Epirubicin + CDDP + 5-FU; Cape.: Capecitabine; Oxal.: Oxaliplatin; peri-op: Peri-operative.

Citation: Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573
URL: https://www.wjgnet.com/1007-9327/full/v20/i33/11567.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i33.11567